Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21012792 | 1.00 | GRM5 (0.31) | GRM5MAP3K12 | |
| SCHEMBL21012853 | 1.00 | GRM5 (0.31) | GRM5MAP3K12 | |
| SCHEMBL20468899 | 1.00 | GRM5 (0.31) | GRM5MAP3K12 | |
| SCHEMBL20469173 | 1.00 | GRM5 (0.31) | GRM5MAP3K12 | |
| SCHEMBL21012906 | 0.83 | — | — | |
| SCHEMBL24018537 | 0.81 | MAP3K12 (0.36) | GRM5MAP3K12 | |
| SCHEMBL20492013 | 0.81 | MAP3K12 (0.44) | MAP3K12 | |
| SCHEMBL20491917 | 0.81 | MAP3K12 (0.44) | MAP3K12 | |
| SCHEMBL23253277 | 0.80 | MAP3K12 (0.32) | MAP3K12 | |
| SCHEMBL21450012 | 0.80 | HCRTR1 (0.35) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11078208-B1 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-10752636-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | GRM5 4058/4885MAP3K12 168/4885 |
| US-11078208-B1 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | GRM5 4058/4885MAP3K12 168/4885 |
| US-10752636-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | GRM5 4058/4885MAP3K12 168/4885 |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | HASPIN, NFATC1, NHERF1 | GRM5 3517/4885MAP3K12 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.